Last 7 days
-16.4%
Last 30 days
-12.3%
Last 90 days
-49.0%
Trailing 12 Months
-96.1%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-08-28 | Brenner Martin | sold | -1,528 | 0.3051 | -5,011 | see remarks |
2023-07-27 | Brenner Martin | sold | -2,307 | 0.511091 | -4,515 | see remarks |
2023-07-12 | Brenner Martin | sold | -27,520 | 0.5853 | -47,020 | see remarks |
2023-06-26 | Brenner Martin | acquired | - | - | 75,833 | see remarks |
2023-06-22 | Brenner Martin | back to issuer | - | - | -75,833 | see remarks |
2023-06-21 | Brenner Martin | sold | -2,848 | 0.680898 | -4,184 | see remarks |
2023-05-22 | Brenner Martin | sold | -3,910 | 0.935057 | -4,182 | see remarks |
2023-04-24 | Brenner Martin | sold | -5,257 | 1.1998 | -4,382 | see remarks |
2023-03-31 | Duran Felipe | acquired | - | - | 37,500 | chief financial officer |
2023-03-31 | Brenner Martin | acquired | - | - | 50,000 | see remarks |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4.95 | -698 | 308 | -% |
2023-08-15 | HARBOUR INVESTMENTS, INC. | unchanged | - | -1,176 | 488 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 13.00 | -139 | 69.00 | -% |
2023-08-15 | Retirement Group, LLC | new | - | 174 | 174 | -% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -1,706 | - | -% |
2023-08-14 | CITADEL ADVISORS LLC | added | 165 | -3,488 | 12,208 | -% |
2023-08-14 | Royal Bank of Canada | reduced | -74.14 | -5,000 | - | -% |
2023-08-14 | VANGUARD GROUP INC | reduced | -1.35 | -767,590 | 312,493 | -% |
2023-08-14 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | sold off | -100 | -52,000 | - | -% |
2023-08-14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 49.00 | 49.00 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 5.28% | 475,593 | SC 13G | |
Jul 08, 2022 | blackrock inc. | 1.8% | 3,960,718 | SC 13G | |
Feb 03, 2022 | blackrock inc. | 7.1% | 15,476,683 | SC 13G/A | |
Feb 02, 2021 | blackrock inc. | 5.5% | 11,575,051 | SC 13G | |
Aug 13, 2020 | eastern capital ltd | 0.6% | 1e+06 | SC 13D/A | |
Aug 11, 2020 | eastern capital ltd | 5.8% | 8,629,693 | SC 13D/A | |
Aug 07, 2020 | eastern capital ltd | 22.3% | 33,114,597 | SC 13D/A | |
Aug 06, 2020 | eastern capital ltd | 22.3% | 33,114,597 | SC 13D/A | |
Mar 31, 2020 | eastern capital ltd | 28.7% | 37,382,734 | SC 13D/A | |
Mar 05, 2020 | eastern capital ltd | 35.6% | 37,382,734 | SC 13D/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Aug 30, 2023 | 4 | Insider Trading | |
Aug 24, 2023 | 4 | Insider Trading | |
Aug 24, 2023 | 4 | Insider Trading | |
Aug 15, 2023 | D | D | |
Aug 14, 2023 | 424B3 | Prospectus Filed | |
Aug 11, 2023 | EFFECT | EFFECT | |
Aug 10, 2023 | CORRESP | CORRESP | |
Aug 09, 2023 | UPLOAD | UPLOAD | |
Aug 07, 2023 | 8-K | Current Report | |
Aug 07, 2023 | 424B5 | Prospectus Filed |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
FATE | 221.7M | - | -17.58% | -90.72% | -1.05 | 1.62 | 116.83% | 16.61% |
SGMO | 146.7M | - | -8.84% | -84.12% | -0.74 | 0.61 | 113.96% | -15.19% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
-44.8%
-57.7%
-56.9%
-82.5%
100%
100%
93.8%
Y-axis is the maximum loss one would have experienced if Ibio was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | - | - | - | 2,383 | 2,543 | 1,508 | 2,045 | 2,371 | 3,000 | 2,331 | 1,940 | 1,638 | 1,313 | 1,744 | 2,081 | 2,018 | 1,314 | 865 | 367 | 444 | 500 | 459 |
Gross Profit | - | - | - | 2,167 | 2,425 | 802 | 1,241 | 909 | 1,890 | 1,628 | 1,512 | 935 | 40.00 | - | - | - | - | - | - | - | - | - |
Operating Expenses | -4.2% | 55,107 | 57,526 | 51,857 | 30,871 | 29,758 | 30,566 | 32,020 | 26,491 | 23,090 | 18,520 | 14,938 | 16,354 | 16,577 | 17,774 | 17,806 | 16,995 | 16,269 | 15,183 | 14,671 | 14,640 | 15,042 |
S&GA Expenses | -4.8% | 35,672 | 37,463 | 34,128 | 21,509 | 21,506 | 21,799 | 22,031 | 19,510 | 17,176 | 14,092 | 11,365 | 11,770 | 11,635 | 12,447 | 12,332 | 12,103 | 11,864 | 11,058 | 10,685 | 10,584 | 10,816 |
R&D Expenses | -3.1% | 19,435 | 20,063 | 17,729 | 9,362 | 8,252 | 8,767 | 9,989 | 6,981 | 5,914 | 4,428 | 3,573 | 4,584 | 4,942 | 5,327 | 5,474 | 4,892 | 4,405 | 4,125 | 3,986 | 4,056 | 4,226 |
Interest Expenses | 4.5% | 805 | 770 | 1,412 | 1,223 | 1,835 | 2,450 | 2,454 | 2,456 | 2,460 | 2,460 | 2,466 | 2,325 | 2,183 | 2,044 | 1,900 | 1,904 | 1,908 | 1,911 | 1,915 | 1,919 | 1,922 |
Net Income | 6.3% | -76,030 | -81,126 | -50,303 | -33,134 | -28,405 | -24,616 | -23,207 | -26,864 | -23,879 | -19,512 | -16,439 | -17,407 | -16,954 | -17,660 | -17,593 | -17,510 | -17,249 | -16,679 | -16,105 | -8,364 | -8,315 |
Net Income Margin | - | - | - | -21.11* | -3.25* | -2.78* | -2.41* | -2.28* | -8.95* | -10.24* | -10.06* | -10.04* | -13.26* | -9.72* | -8.49* | -8.72* | - | - | - | - | - | - |
Free Cashflow | 6.0% | -45,631 | -48,548 | -44,810 | -39,617 | -41,371 | -37,965 | -34,984 | -29,918 | -25,431 | -19,625 | -14,423 | -14,285 | -14,693 | -16,130 | - | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Assets | -14.3% | 44.00 | 52.00 | 85.00 | 99.00 | 115 | 126 | 144 | 147 | 143 | 145 | 117 | 94.00 | 42.00 | 36.00 | 35.00 | 31.00 | 36.00 | 40.00 | 43.00 | 43.00 | 31.00 |
Current Assets | -29.1% | 27.00 | 38.00 | 64.00 | 45.00 | 60.00 | 67.00 | 90.00 | 105 | 107 | 111 | 85.00 | 62.00 | 10.00 | 4.00 | 2.00 | 5.00 | 10.00 | 14.00 | 16.00 | 16.00 | 4.00 |
Cash Equivalents | 77.5% | 7.00 | 4.00 | 10.00 | 23.00 | 40.00 | 45.00 | 63.00 | 77.00 | 85.00 | 91.00 | 78.00 | 55.00 | 10.00 | 4.00 | 2.00 | 4.00 | 9.00 | 13.00 | 8.00 | 4.00 | 3.00 |
Inventory | - | - | - | - | 4.00 | 3.00 | 2.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 2.7% | 4.00 | 4.00 | 3.00 | 1.00 | 35.00 | 33.00 | 10.00 | 9.00 | 6.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 24.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 |
Liabilities | -18.1% | 27.00 | 33.00 | 36.00 | 36.00 | 36.00 | 36.00 | 43.00 | 38.00 | 38.00 | 38.00 | 37.00 | 38.00 | 38.00 | 37.00 | 37.00 | 28.00 | 29.00 | 29.00 | 30.00 | 27.00 | 27.00 |
Current Liabilities | -19.8% | 22.00 | 28.00 | 32.00 | 30.00 | 8.00 | 8.00 | 8.00 | 7.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 5.00 | 3.00 | 4.00 | 4.00 | 5.00 | 2.00 | 2.00 |
Shareholder's Equity | -7.6% | 17.00 | 19.00 | 48.00 | 63.00 | 79.00 | 91.00 | 101 | 109 | 105 | 107 | 80.00 | 57.00 | 4.00 | - | - | 2.00 | 7.00 | 11.00 | 13.00 | 16.00 | 4.00 |
Retained Earnings | -2.6% | -282 | -275 | -242 | -223 | -206 | -194 | -182 | -173 | -173 | -166 | -157 | -150 | -146 | -135 | -110 | -105 | -101 | -97.09 | -92.63 | -88.23 | -83.81 |
Additional Paid-In Capital | 1.9% | 300 | 295 | 291 | 288 | 286 | 285 | 283 | 282 | 278 | 273 | 238 | 207 | 151 | 135 | 108 | 108 | 108 | 108 | 106 | 104 | 88.00 |
Shares Outstanding | 0% | 12.00 | 12.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Minority Interest | - | - | - | - | - | - | - | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Cashflow From Operations | 5.3% | -36,969 | -39,041 | -42,092 | -37,480 | -33,203 | -34,608 | -32,341 | -30,064 | -26,705 | -23,142 | -18,128 | -13,345 | -13,870 | -14,219 | -15,484 | -13,975 | -12,958 | -12,323 | -11,241 | -13,480 | -13,870 |
Share Based Compensation | 6.7% | 5,124 | 4,802 | 4,778 | 4,377 | 3,794 | 2,894 | 2,056 | 1,586 | 1,210 | 899 | 671 | 388 | 227 | 213 | 236 | 241 | 375 | 509 | 638 | 770 | 874 |
Cashflow From Investing | 3329.3% | 7,492 | -232 | 51.00 | -5,127 | -8,512 | -13,043 | -25,027 | -26,478 | -24,390 | -20,472 | -7,724 | -1,154 | -507 | -550 | -731 | -990 | -1,099 | -1,445 | -1,257 | -1,079 | -1,322 |
Cashflow From Financing | 76.7% | -449 | -1,923 | -4,896 | -6,125 | -3,203 | 1,545 | 42,646 | 78,835 | 125,682 | 131,231 | 101,293 | 65,192 | 15,383 | 5,046 | 2,310 | 3,453 | 19,695 | 19,820 | 22,593 | 22,406 | 6,170 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||
Revenues | $ 0 | $ 0 | $ 84 | |
Operating expenses: | ||||
Research and development | 2,779 | 1,859 | $ 5,327 | 2,993 |
General and administrative | 7,794 | 5,372 | 12,882 | 9,547 |
Total operating expenses | 10,573 | 7,231 | 18,209 | 12,540 |
Operating loss | (10,573) | (7,231) | (18,209) | (12,456) |
Other income (expense): | ||||
Interest expense | (31) | 0 | (31) | |
Interest income | 41 | 35 | 140 | 71 |
Royalty income | 0 | 5 | 5 | |
Total other income (expense) | 10 | 40 | 109 | 76 |
Consolidated net loss from continuing operations | (10,563) | (7,191) | (18,100) | (12,380) |
Net loss attributable to noncontrolling interest | 0 | 0 | 1 | |
Net loss attributable to iBio, Inc. from continuing operations | (10,563) | (7,191) | (18,100) | (12,379) |
Preferred stock dividends - iBio CDMO Tracking Stock | 0 | (22) | 0 | (88) |
Net loss available to iBio, Inc. stockholders from continuing operations | (10,563) | (7,213) | (18,100) | (12,467) |
Loss from discontinued operations | (22,990) | (4,729) | (33,583) | (8,480) |
Net loss available to iBio, Inc. stockholders | (33,553) | (11,942) | (51,683) | (20,947) |
Comprehensive loss: | ||||
Consolidated net loss | (33,553) | (11,920) | (51,683) | (20,860) |
Other comprehensive loss - unrealized gain ( loss) on debt securities | 56 | (27) | 46 | (28) |
Comprehensive loss | $ (33,497) | $ (11,947) | $ (51,637) | $ (20,888) |
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations | $ (1.08) | $ (0.83) | $ (1.94) | $ (1.43) |
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations | (1.08) | (0.83) | (1.94) | (1.43) |
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations | (2.34) | (0.54) | (3.60) | (0.97) |
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations | (2.34) | (0.54) | (3.60) | (0.97) |
Loss per common share attributable to iBio, Inc. stockholders - basic - total | (3.42) | (1.37) | (5.54) | (2.40) |
Loss per common share attributable to iBio, Inc. stockholders - diluted - total | $ (3.42) | $ (1.37) | $ (5.54) | $ (2.40) |
Weighted-average common shares outstanding - basic | 9,807 | 8,715 | 9,324 | 8,715 |
Weighted-average common shares outstanding - diluted | 9,807 | 8,715 | 9,324 | 8,715 |
Condensed Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Jun. 30, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,696,000 | $ 22,676,000 |
Investments in debt securities | 5,929,000 | 10,845,000 |
Accounts receivable - trade | 970,000 | 1,000,000 |
Settlement receivable - current portion | 5,100,000 | 5,100,000 |
Convertible promissory note receivable and accrued interest | 1,669,000 | |
Prepaid expenses and other current assets | 414,000 | 1,549,000 |
Current assets held for sale | 20,457,000 | 3,900,000 |
Total Current Assets | 38,235,000 | 45,070,000 |
Restricted cash | 253,000 | 5,996,000 |
Convertible promissory note receivable and accrued interest | 1,631,000 | |
Finance lease right-of-use assets, net of accumulated amortization | 746,000 | |
Operating lease right-of-use asset | 2,873,000 | 3,068,000 |
Fixed assets, net of accumulated depreciation | 4,245,000 | 1,373,000 |
Intangible assets, net of accumulated amortization | 5,398,000 | 4,851,000 |
Security deposits | 50,000 | 29,000 |
Prepaid expenses - noncurrent | 74,000 | |
Noncurrent assets held for sale | 37,314,000 | |
Total Assets | 51,800,000 | 99,406,000 |
Current liabilities: | ||
Accounts payable | 4,002,000 | 4,264,000 |
Accrued expenses | 5,001,000 | 3,764,000 |
Finance lease obligations - current portion | 259,000 | |
Operating lease obligation - current portion | 315,000 | 91,000 |
Equipment financing payable - current portion | 152,000 | |
Term note payable - net of deferred financing costs | 16,011,000 | 22,161,000 |
Contract liabilities | 88,000 | 100,000 |
Current liabilities related to assets held for sale | 1,947,000 | 56,000 |
Total Current Liabilities | 27,775,000 | 30,436,000 |
Finance lease obligations - net of current portion | 490,000 | |
Operating lease obligation - net of current portion | 3,324,000 | 3,514,000 |
Equipment financing payable - net of current portion | 323,000 | |
Accrued expenses - noncurrent | 1,065,000 | |
Noncurrent liabilities related to assets held for sale | 1,971,000 | |
Total Liabilities | 32,977,000 | 35,921,000 |
iBio, Inc. Stockholders' Equity: | ||
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively | ||
Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2022 and June 30, 2022; 12,368,287 and 8,727,158 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively | 12,000 | 9,000 |
Additional paid-in capital | 294,591,000 | 287,619,000 |
Accumulated other comprehensive loss | (167,000) | (213,000) |
Accumulated deficit | (275,613,000) | (223,930,000) |
Total iBio, Inc. Stockholders' Equity | 18,823,000 | 63,485,000 |
Total Liabilities and Equity | $ 51,800,000 | $ 99,406,000 |